Literature DB >> 8855304

Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in vivo: a comprehensive study of all its components in the dog.

Y A Lee1, C S Liang, M A Lee, K Lindpaintner.   

Abstract

Cardiac hypertrophy is associated with altered expression of the components of the cardiac renin-angiotensin system (RAS). While in vitro data suggest that local mechanical stimuli serve as important regulatory modulators of cardiac RAS activity, no in vivo studies have so far corroborated these observations. The aims of this study were to (i) examine the respective influence of local, mechanical versus systemic, soluble factors on the modulation of cardiac RAS gene expression in vivo; (ii) measure gene expression of all known components of the RAS simultaneously; and (iii) establish sequence information and an assay system for the RAS of the dog, one of the most important model organisms in cardiovascular research. We therefore examined a canine model of right ventricular hypertrophy and failure (RVHF) in which the right ventricle (RV) is hemodynamically loaded, the left ventricle (LV) is hemodynamically unloaded, while both are exposed to the same circulating milieu of soluble factors. Using specific competitive PCR assays, we found that RVHF was associated with significant increases in RV mRNA levels of angiotensin converting enzyme and angiotensin II type 2 receptor, and with significant decreases of RV expression of chymase and the angiotensin II type 1 receptor, while RV angiotensinogen and renin remained unchanged. All components remained unchanged in the LV. We conclude that (i) dissociated regional regulation of RAS components in RV and LV indicates modulation by local, mechanical, not soluble, systemic stimuli; (ii) components of the cardiac RAS are independently and differentially regulated; and (iii) opposite changes in the expression of angiotensin converting enzyme and chymase, and of angiotensin II type I and angiotensin II type 2 receptors, may indicate different physiological roles of these RAS components in RVHF.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8855304      PMCID: PMC38279          DOI: 10.1073/pnas.93.20.11035

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Role of right heart receptors in the control of renin, vasopressin, and cortisol secretion in dogs.

Authors:  D H Carr; D B Jennings; T N Thrasher; L C Keil; D J Ramsay
Journal:  Am J Physiol       Date:  1992-11

2.  Angiotensin II receptor subtypes play opposite roles in regulating phosphatidylinositol hydrolysis in rat skin slices.

Authors:  R Gyurko; B Kimura; P Kurian; F T Crews; M I Phillips
Journal:  Biochem Biophys Res Commun       Date:  1992-07-15       Impact factor: 3.575

3.  Vasoconstrictor action of angiotensin I-convertase and the synthetic substrate (Pro11,D-Ala12)-angiotensin I.

Authors:  M L Mangiapane; A L Rauch; J T MacAndrew; S S Ellery; K W Hoover; D R Knight; H A Johnson; W P Magee; D J Cushing; R A Buchholz
Journal:  Hypertension       Date:  1994-06       Impact factor: 10.190

4.  Selective activation of cardiac angiotensinogen gene expression in post-infarction ventricular remodeling in the rat.

Authors:  K Lindpaintner; W Lu; N Neidermajer; B Schieffer; H Just; D Ganten; H Drexler
Journal:  J Mol Cell Cardiol       Date:  1993-02       Impact factor: 5.000

5.  Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype.

Authors:  J Sadoshima; S Izumo
Journal:  Circ Res       Date:  1993-09       Impact factor: 17.367

6.  Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy.

Authors:  J Suzuki; H Matsubara; M Urakami; M Inada
Journal:  Circ Res       Date:  1993-09       Impact factor: 17.367

7.  Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro.

Authors:  J Sadoshima; Y Xu; H S Slayter; S Izumo
Journal:  Cell       Date:  1993-12-03       Impact factor: 41.582

8.  Characterization of angiotensin II receptor subtypes in rat heart.

Authors:  L A Sechi; C A Griffin; E F Grady; J E Kalinyak; M Schambelan
Journal:  Circ Res       Date:  1992-12       Impact factor: 17.367

9.  Intracardiac detection of angiotensinogen and renin: a localized renin-angiotensin system in neonatal rat heart.

Authors:  D E Dostal; K N Rothblum; M I Chernin; G R Cooper; K M Baker
Journal:  Am J Physiol       Date:  1992-10

10.  Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding.

Authors:  A M Feldman; E O Weinberg; P E Ray; B H Lorell
Journal:  Circ Res       Date:  1993-07       Impact factor: 17.367

View more
  4 in total

Review 1.  Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications.

Authors:  Seema A Kothari; Mytrang K Le; Pritesh J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

2.  Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects.

Authors:  H Masaki; T Kurihara; A Yamaki; N Inomata; Y Nozawa; Y Mori; S Murasawa; K Kizima; K Maruyama; M Horiuchi; V J Dzau; H Takahashi; T Iwasaka; M Inada; H Matsubara
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

Review 3.  Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies.

Authors:  John W Wright; Shigehiko Mizutani; Joseph W Harding
Journal:  Heart Fail Rev       Date:  2007-11-07       Impact factor: 4.214

Review 4.  Cardiovascular effects of losartan and its relevant clinical application.

Authors:  Feichao Xu; Caiping Mao; Yali Hu; Can Rui; Zhice Xu; Lubo Zhang
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.